ArticleMolecular biology reports2026
Lactic acid bacteria bacteriocins as novel antimicrobials against antibiotic-resistant Streptococcus pneumoniae in opthalamic infections.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOphthalmic infections, including conjunctivitis and keratitis, caused by Streptococcus pneumoniae may lead to significant ocular morbidity. Rising antibiotic resistance among ocular pathogens has reduced the efficacy of conventional treatments highlighting the need for alternative antimicrobial strategies. This study aimed to evaluate the antimicrobial potential of bacteriocins produced by lactic acid bacteria (LAB) against antibiotic-resistant Streptococcus pneumoniae isolated from clinical ophthalmic samples and to compare their efficacy with conventional antibiotics.
methodsA total of 230 eye swab samples were collected from patients attending Rashid Latif Medical Complex (RLMC), Lahore, Pakistan. S. pneumoniae isolates were identified using morphological, biochemical, and 16 S rRNA gene sequencing methods. Antibiotic susceptibility was performed using the agar well diffusion method. LAB strains from milk, curd, and pickle samples were identified by 16 S rRNA sequencing and screened for bacteriocin-mediated inhibitory activity against S. pneumoniae. Bacteriocin concentrations were quantified using the Bradford assay, and molecular weight was determined by SDS-PAGE.
resultsFour S. pneumoniae isolates exhibited varying resistance patterns, including resistance to ciprofloxacin and gentamicin. LAB strains, particularly Enterococcus faecium and Ligilactobacillus salivarius, demonstrated inhibitory activity against S. pneumoniae, with inhibition zones of up to 8.6 mm. Bacteriocin concentrations ranged from 3.55 to 7.17 µg/mL, with an estimated molecular weight of ~ 3.5 kDa.
conclusionLAB-derived bacteriocins exhibit promising antibacterial activity against antibiotic-resistant S. pneumoniae, suggesting their potential as cost-effective and sustainable alternatives to conventional antibiotics for ophthalmic infections. Further studies on purification, formulation, and in vivo evaluation are required to advance bacteriocin-based therapeutics toward clinical application.
Indexed as
Identifiers
42479249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.